On the Record · LivaNova
LivaNova acquisitions, on the record
The businesses LivaNova bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Heart Valve businessWord for word“The sale of the Heart Valve business closed on June 1, 2021.” 10-K for 2023 | agreed divestiture | June 1, 2021 | — |
ALungWord for word“On May 2, 2022, LivaNova acquired the remaining 97 % of equity interests in ALung for a purchase price of up to $ 110.0 million, consisting of $ 10.0 million paid at closing, subject to F-15 customary adjustments, and contingent consideration of up to $ 100.0 million payable upon achievement of certain sales-based milestones beginning in 2023 and ending in 2027.” 10-K for 2023 | acquisition | May 2, 2022 | — |
Advanced Circulatory Support (ACS) segment wind downWord for word“For example, as part of the 2024 Restructuring Plan, the Company will wind down the ACS segment, which is anticipated to be substantially complete by the end of 2024.” 10-K for 2023 | divestiture | — | — |
ImThera Medical, Inc.Word for word“In 2018, LivaNova acquired full ownership of ImThera, a company developing an implantable neurostimulation device system for the treatment of obstructive sleep apnea.” 10-K for 2024 | acquisition | 2018 | — |
Heart ValvesWord for word“Proceeds from deferred consideration from sale of Heart Valves, net of working capital adjustments” 10-K for 2024 | divestiture | — | — |
SorinWord for word“For example, LivaNova is currently in litigation with the government in Italy stemming from a civil action where the Court of Appeal declared LivaNova (formed through a merger with Sorin) liable for environmental liabilities incurred by SNIA’s (a former parent company of Sorin) other subsidiaries.” 10-K for 2024 | merger | — | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $0 | — | $763.1 million |
| 2017-12-31 | $14.2 million | $4.9 million | $42.4 million |
| 2018-12-31 | $279.7 million | — | $204 million |
| 2019-12-31 | $10.8 million | — | $1.6 million |
| 2020-12-31 | $1.7 million | — | — |
| 2021-12-31 | $1.7 million | — | — |
| 2022-12-31 | $8.9 million | — | $25.9 million |
| 2023-12-31 | $0 | — | — |
| 2024-12-31 | $0 | — | — |
Deal filings since 2016
- 2024-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-07-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-03-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-08-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-04-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-02-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-12-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-06-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-06-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-04-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-03-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-03-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-04-30 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2018-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-11-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from LivaNova’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-25. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.